Table 2 Biological agents in ankylosing spondylitis
Name | Biologic class | Half-life | Administration | Frequency | Published randomised control trial data |
|---|---|---|---|---|---|
Infliximab | Chimeric TNF inhibitor | 8 to 9 days | Intravenous | Every 6 to 8 weeks | 5 years [11] |
Etanercept | Fusion protein TNF inhibitor | 70 hours | Subcutaneous | Twice a week or weekly | 5 years [92] |
Adalimumab | Fully human TNF inhibitor | 2 weeks | Subcutaneous | Fortnightly | 3 years [38] |
Golimumab | Fully human TNF inhibitor | 2 weeks | Subcutaneous | Every 4 weeks | 24 weeks [14] |
Rituximab | Anti-CD20 (anti-β cell) | 3 weeks | Intravenous | Two doses | 24 weeks [15] |
Ustekinumab | Fully human IL-12 and IL-23 inhibitor | 3 weeks | Subcutaneous | Every 4 weeks in psoriatic arthritis | None |
Anakinra | IL-1 inhibitor | 4 to 6 hours | Subcutaneous | Daily | 24 weeks [17] |